Studies
Every study, review and regulatory document in the collection, newest first. Each links to a page with its population, findings, funding and original source.
01Find
Filter studies
8 studies · Download as JSON
- Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
- Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 3 · Different population · Unclear · Industry funded · Unreviewed automatic assessment
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsTrial registration · 2026 · Preliminary · Different population · Unclear · Industry funded
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
- Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialRandomized trial · 2023 · Study tier 2 · Different population · Mixed · Industry funded